立体定向消融放疗用于转移性胰腺癌姑息治疗的效用
本研究回顾了2002至2018年间接受原发灶立体定向消融放疗(SABR)的27例转移性胰腺癌患者,评估其疼痛缓解、阿片类药物使用及毒性。中位随访6个月,中位总生存7个月,1年局部失败累积发生率25%;结论认为SABR是转移性胰腺癌局部姑息的安全有效选择。
要点
- 中位总生存7个月(95%CI 3-10),1年局部失败累积发生率25%(95%CI 10-44)。
- 仅2例(7%)出现归因于治疗的3级毒性。
核心结论
- 在这小样本系列中,SABR是转移性胰腺癌局部姑息的安全有效选择,可测量地改善腹痛及阿片类药物需求。
研究设计与样本
- 回顾性分析2002至2018年接受原发灶SABR的转移性胰腺癌患者记录,共纳入27例符合标准者。
- 17例(63%)接受单次SABR,中位剂量25 Gy(范围12.5-25);10例(37%)接受5次SABR,中位剂量33 Gy(范围25-40)。
- 毒性按NCI CTCAE v4.03分级,疼痛强度按Stanford疼痛量表由患者报告,时间-事件从SABR结束日计算。
主要发现
- SABR前17例(63%)报告腹痛,中位强度5分(0-10量表,范围1-9),其中11例(41%)需持续阿片类药物。
- 中位随访6个月(范围0-18),中位总生存7个月(95%CI 3-10),1年局部失败累积发生率25%(95%CI 10-44)。
- 仅2例(7%)出现可归因于治疗的3级毒性。
关键数值与推荐
- 单次SABR中位剂量25 Gy(范围12.5-25),5次SABR中位剂量33 Gy(范围25-40)。
- 疼痛强度采用0-10分Stanford疼痛量表,毒性采用NCI CTCAE v4.03分级。
临床怎么用
- 对转移性胰腺癌原发灶可考虑SABR以局部姑息减轻腹痛并减少阿片类药物使用。
- 治疗决策需权衡SABR的3级毒性风险(本系列为7%)。
局限性
- 样本量小(27例),为回顾性系列。
- 中位随访仅6个月(范围0-18),随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to report the outcome of stereotactic ablative radiation therapy (SABR) to the primary tumor for patients with metastatic pancreatic cancer. METHODS AND MATERIALS: We examined the records of patients with metastatic pancreatic cancer treated with SABR to the primary tumor between 2002 and 2018. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03. Pain intensity pre- and post-SABR was scored according to the Stanford Pain Scale as reported by the patient. Time-to-events were calculated from the date of end of SABR delivery. RESULTS: In total, 27 patients were identified that met the inclusion criteria. Seventeen (63%) patients received single fraction SABR with a median dose of 25 Gy (range, 12.5-25), and 10 (37%) patients were treated in 5 fractions with a median dose of 33 Gy (range, 25-40). Before the start of SABR, 17 (63%) patients reported having abdominal pain, with a median intensity of 5 in the 0 to 10 pain scale (range, 1-9), 11 (41%) of them needing continuous opioid use. The median follow-up was 6 months (range, 0-18). Median overall survival was 7 months (95% confidence interval, 3-10), with a cumulative incidence of local failures at 1 year of 25% (95% confidence interval, 10-44). After SABR, there was a significant reduction in the mean intensity of pain (P = .01), and a 46% relative reduction in continuous opioid use. Only 2 patients (7%) presented a grade 3 toxicity that could be attributed to treatment. CONCLUSIONS: In this small series, SABR was a safe and effective option for the local palliation of metastatic pancreatic cancer, with measurable improvements in abdominal pain and the need for opioids.
引用
- Koong AJ, Toesca DAS, Baclay JRM, et al. The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. Pract Radiat Oncol. 2020. PMID: 32119922. doi:10.1016/j.prro.2020.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。